ReviewHematology. American Society of Hematology. Education Program2016
Platelets in liver and renal disease.
Review in Hematology. American Society of Hematology. Education Program, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 64 citations in OpenAlex.
- Childhood Liver-Related Abnormalities After Fontan Completion: Evidence from a 20-Year Tertiary Centre Cohort.Pediatric cardiology · 2026Article
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Automated machine learning model to predict anti-tuberculosis drug-induced liver injury in patients with tuberculous meningitis.Frontiers in pharmacology · 2026Article
- Prevalence and factors associated with severe thrombocytopenia among hospitalized patients with malaria attending Kigeme District Hospital, Southern Province, Rwanda: cross-sectional study.Malaria journal · 2025Article
- Salvianolic acid A inhibits the activation and aggregation of platelets in patients with acute coronary syndrome.Medicine · 2025Article
- Ascites in patients with end-stage renal disease: Challenges and solutions from diagnosis to management.Hepatology communications · 2025Review
- Clinical implications of the MELD-XI score in patients undergoing percutaneous coronary intervention: Insights from the SAKURA PCI2 Antithrombotic registry.International journal of cardiology. Heart & vasculature · 2025Article
- Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis.Thrombosis journal · 2024Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- Exploring ideal operative time for best outcomes in gastric cancer surgery: A multi-institutional study based on KLASS-07 database.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- End-stage renal disease patients have comparable results to renal transplant patients after shoulder arthroplasty.JSES international · 2023Article
- Selective Internal Radiotherapy Alters the Profiles of Systemic Extracellular Vesicles in Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Review
- Macrophages and platelets in liver fibrosis and hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Association of longitudinal platelet count trajectory with ICU mortality: A multi-cohort study.Frontiers in immunology · 2022Article
- Cadmium exposure modulates the gut-liver axis in an Alzheimer's disease mouse model.Communications biology · 2021Article
- Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease.Healthcare (Basel, Switzerland) · 2021Article
- Heparin-induced thrombocytopenia in end-stage renal disease: Reliability of the PF4-heparin ELISA.Research and practice in thrombosis and haemostasis · 2021Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review will discuss how 2 common and morbid conditions, renal disease and liver disease, alter platelet number and function. It will review the impact of thrombocytopenia on bleeding complications in patients with these disorders and whether the low platelet count actually correlates with bleeding risk. Emerging data also suggest that platelets are much more than bystanders in both renal and liver disease, but instead play an active role in the pathobiology of these disorders. This review will briefly cover the emerging information on novel roles of platelets in the biology of renal and liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.